Can CD47 antibody therapy be safely used for AML and MDS?
AML Hub22 Kesä 2020

Can CD47 antibody therapy be safely used for AML and MDS?

During the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US.


The question was, Is CD47-directed antibody therapy safe and effective in patients with AML and myelodysplastic syndromes?


CD47 is a dominant negative immune checkpoint expressed by cancer cells, which facilitates immune evasion by decreasing recognition by macrophages. Increased expression of CD47 on cancer cells has been associated with inferior survival in patients with AML. The first-in-class anti-CD47 antibody magrolimab reinstates macrophage-mediated phagocytosis of tumor cells and has demonstrated anti-tumor activity in preclinical models.


Here, David Sallman and Naval Daver discuss the potential and clinical status of CD47-directed antibody therapy for the treatment of AML and myelodysplastic syndromes.

Hosted on Acast. See acast.com/privacy for more information.

Jaksot(33)

Know AML webinar | Closing remarks and Q&A

Know AML webinar | Closing remarks and Q&A

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the...

26 Kesä 20259min

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hoste...

19 Kesä 20259min

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz...

13 Kesä 202527min

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charl...

9 Kesä 202513min

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission p...

3 Loka 20245min

CPX-351 as first-line treatment in AML: Real-world data

CPX-351 as first-line treatment in AML: Real-world data

Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy fo...

30 Syys 202416min

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consens...

17 Syys 202413min

What were your highlights from ASH 2023?

What were your highlights from ASH 2023?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. Se...

29 Huhti 20243min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
voi-hyvin-meditaatiot-2
psykopodiaa-podcast
adhd-podi
rss-narsisti
psykologia
kesken
rss-vapaudu-voimaasi
rahapuhetta
rss-niinku-asia-on
rss-liian-kuuma-peruna
rss-duodecim-lehti
rss-valo-minussa-2
rss-luonnollinen-synnytys-podcast
rss-tietoinen-yhteys-podcast-2
aamukahvilla
rss-uskonto-on-tylsaa
rss-honest-talk-with-laurrenna
nakokulmia-rikollisuudesta-irrottautumiseen
rss-ai-mita-siskopodcast